Reported about 20 hours ago
Moderna has lowered its 2025 revenue forecast by $1 billion, now anticipating between $1.5 billion and $2 billion, citing weak demand for its latest vaccine and sluggish sales of its COVID-19 vaccine. Following this announcement at the JPMorgan healthcare conference, Moderna's stock plummeted over 20%. The company also faces challenges with other products in its pipeline and aims to continue cutting costs into 2025.
Source: YAHOO